Abstract
The haemodynamic effects of intravenous mexiletine have been studied in 16 patients with valvular heart disease without clinical evidence of heart failure. A bolus injection of 150 mg administered to 6 of the 16 patients resulted in a mean plasma concentration above the therapeutic range for at least 5 minutes after the drug was given. A small but significant rise in the mean pulmonary artery pressure occurred. In 10 patients, the effects of intravenous mexiletine were compared with those of intravenous saline in a double blind trial. No significant difference was found in the haemodynamic effects, though both saline and mexiletine produced a small rise in the mean pulmonary artery pressure. Mexiletine when administered to patients without heart failure in doses known to be clinically effective did not have important adverse haemodynamic effects.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Banim S. O., Da Silva A., Stone D., Balcon R. Observations of the haemodynamics of mexiletine. Postgrad Med J. 1977;53 (Suppl 1):74–77. [PubMed] [Google Scholar]
- Campbell N. P., Chaturvedi N. C., Shanks R. G., Kelly J. G., Strong J. E., Adgey A. A. The development of mexiletine in the management of ventricular dysrhythmias. Postgrad Med J. 1977;53 (Suppl 1):114–119. [PubMed] [Google Scholar]
- Campbell N. P., Kelly J. G., Adgey A. A., Shanks R. G. The clinical pharmacology of mexiletine. Br J Clin Pharmacol. 1978 Aug;6(2):103–108. doi: 10.1111/j.1365-2125.1978.tb00833.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Campbell R. W., Dolder M. A., Prescott L. F., Talbot R. G., Murray A., Julian D. G. Ventricular arrhythmias after acute myocardial infarction treated with procainamide or mexiletine. Postgrad Med J. 1977;53 (Suppl 1):150–153. [PubMed] [Google Scholar]
- Kelly J. G. Measurement of plasma mexiletine concentrations. Postgrad Med J. 1977;53 (Suppl 1):48–49. [PubMed] [Google Scholar]
- Pozenel H. Haemodynamic studies on mexiletine, anew antiarrhythmic agent. Postgrad Med J. 1977;53 (Suppl 1):78–80. [PubMed] [Google Scholar]
- Prescott L. F. The development of intravenous mexiletine dose regimes. Postgrad Med J. 1977;53 (Suppl 1):124–127. [PubMed] [Google Scholar]
- Russell R. O., Jr, Rackley C. E., Pombo J., Hunt D., Potanin C., Dodge H. T. Effects of increasing left ventricular filling. Pressure in patients with acute myocardial infarction. J Clin Invest. 1970 Aug;49(8):1539–1550. doi: 10.1172/JCI106371. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Saunamäki Haemodynamic effects of a new anti-arrhythmic agent, mexiletine (Kö 1173) in ischaemic heart disease. Cardiovasc Res. 1975 Nov;9(6):788–792. doi: 10.1093/cvr/9.6.788. [DOI] [PubMed] [Google Scholar]
- Shaw T. R. The effect of mexiletine on left ventricular ejection: a comparison with lignocaine and propranolol. Postgrad Med J. 1977;53 (Suppl 1):69–73. [PubMed] [Google Scholar]